event-driven endpoint Obstructive Sleep Apnea Status: Phase 3 Planned Focus: OSA severity reduction (apnea-hypopnea index) with CagriSema-induced weight loss Population: Adults with moderate-severe OSA and obesity Timeline: Expected enrollment 2024-2025 NASH/MAFLD Status: Phase 2 Ongoing Focus: Hepatic steatosis, inflammation, and fibrosis improvement Population: Adults with biopsy-confirmed NASH/MAFLD Timeline: Results expected 2025 Heart Failure with Preserved EF Status: Preclinical Planning Focus: HFpEF outcomes in obese patients following substantial weight loss Rationale: Obesity-HFpEF phenotype may benefit from profound weight reduction Timeline: Early development phase Pediatric Obesity Status: Phase 2 Planning Focus: Safety, tolerability, and efficacy in adolescents (12-18 years) Population: Adolescents with obesity (BMI 95th percentile) Timeline: Expected initiation 2025 Oral Formulation Development Status: Preclinical Focus: Oral bioavailability enhancement for cagrilintide using absorption enhancers Rationale: Oral delivery could improve accessibility and adherence Timeline: Research phase
At First Choice Immediate Care, we provide: Occupational health services Lab testing and immunisations Treatment for minor illnesses and non-life-threatening injuries Whether its a B12 boost or help with a lingering cold, were here with high-quality care, extended hours, and modern technology
Treatment The injection is typically administered into the deltoid (shoulder), vastus lateralis (thigh), or ventrogluteal (side of the hip) muscle
Neurons depend heavily on oxidative phosphorylation and calcium buffering, whereas astrocytes can increase glycolysis and shuttle lactate [11, 12]
It is an unapproved investigational research chemical presented here for research and educational purposes only
